Q-omics provides the consensus-scored UNC93B8 profile across patient tissues and cancer cell-line models. UNC93B8 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, UNC93B8 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, UNC93B8 RNA expression shows 4,781 significant pathway-activity associations, with the highest sampling consensus in THCA. Together, these results highlight LUSC, LUAD, and THCA as cancer lineages where UNC93B8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UNC93B8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UNC93B8 survival associations across molecular data types. UNC93B8 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UNC93B8 RNA expression–survival associations across cancer types. High UNC93B8 expression shows unfavorable associations in CHOL, BRCA, SKCM and ACC, but favorable associations in LUSC and BLCA. The LUSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUSC as the clearest survival context for UNC93B8 RNA expression.
This table summarizes UNC93B8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for UNC93B8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UNC93B8 shows lower tumor expression in KICH and higher tumor expression in LUAD, STAD, COAD and HNSC. The LUAD box plot shows higher UNC93B8 RNA expression in tumor versus normal tissue (log2 FC = +0.080, t-test p = .002).
This table shows molecular features associated with UNC93B8 in patient tissues and cancer cell lines. In patient samples, UNC93B8 shows the broadest associations at the RNA and protein expression levels, with THCA recurring as the lineage with the largest associated feature set.
